Literature DB >> 22754589

Pathways and biomarkers in breast cancer: latest evidence.

Gordon Mallarkey1, R Charles Coombes.   

Abstract

Entities:  

Year:  2012        PMID： 22754589      PMCID： PMC3384096          DOI： 10.1177/1758834012450600

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  3 in total

1.  Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

Authors:  I Treilleux; M Arnedos; C Cropet; Q Wang; J-M Ferrero; S Abadie-Lacourtoisie; C Levy; E Legouffe; A Lortholary; E Pujade-Lauraine; A-V Bourcier; J-C Eymard; D Spaeth; T Bachelot
Journal:  Ann Oncol       Date:  2014-10-31       Impact factor: 32.976

2.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Authors:  Aleix Prat; Maggie Chon U Cheang; Miguel Martín; Joel S Parker; Eva Carrasco; Rosalía Caballero; Scott Tyldesley; Karen Gelmon; Philip S Bernard; Torsten O Nielsen; Charles M Perou
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

3.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.

Authors:  Gunter von Minckwitz; Sherko Kümmel; Petra Vogel; Claus Hanusch; Holger Eidtmann; Jörn Hilfrich; Bernd Gerber; Jens Huober; Serban Dan Costa; Christian Jackisch; Sibylle Loibl; Keyur Mehta; Manfred Kaufmann
Journal:  J Natl Cancer Inst       Date:  2008-04-08       Impact factor: 13.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.